Check out some of the companies making the biggest moves midday: Hims & Hers Health – Shares of the telehealth company jumped 3%. Bank of America upgraded the stock to neutral from underperform after Novo Nordisk dropped its patent infringement case against Hims, and the companies agreed that Hims would sell Novo’s Ozempic and Wegovy drugs on its platform. Novo’s move to drop the case is “a clear positive in our view as it removes litigation and related credit risk – the primary driver of the new and higher multiple in our model,” wrote analyst Allen Lutz in a Tuesday note. BioNTech – U.S.-traded shares of the German biotech company cratered more than 20%. BioNTech announced that its co-founders, Prof. Ugur Sahin, M.D. and Prof. Özlem Türeci, M.D., would leave to establish and lead an independent company. Separately, BioNTech reported a fourth-quarter net loss of 305 million euros. SolarEdge Technologies — The solar stock surged nearly 10% after Bank of America upgraded it to neutral from underperform. The Wall Street firm said SolarEdge’s margin trajectory, revenue cadence and liquidity have all stabilized enough to materially reduce downside risk. West Pharmaceutical Services — The drugmaker fell 6% after it said CEO and chairman Eric Green will retire in the second half of 2026. United Natural Foods — Shares lost almost 3%. The grocery distributor reported revenue of $7.95 billion in its fiscal second quarter, short of the $8.11 billion expected by analysts polled by FactSet. United Natural also lowered its full-year revenue guidance and now anticipates a range of $31 billion to $31.4 billion, versus prior guidance of $31.6 billion to $32 billion. Kohl’s — Shares rose 1% after the retailer reiterated that it was working on a turnaround plan. Kohls tumbled posted disappointing fourth-quarter revenue of $4.97 billion, below the LSEG consensus of $5.03 billion, while fourth-quarter adjusted earnings of $1.07 per share topped the expected 85 cents per share. Casey’s General Stores — The convenience store chain added nearly 2%. Earnings in the third quarter came in at $3.49 per share, topping the FactSet consensus estimate of $3 per share. Revenue missed analyst estimates, coming in at $3.92 billion against a consensus forecast of $4.04 billion. UWM Holdings – The mortgage originator advanced almost 7%. UWM lifted its first-quarter revenue outlook, calling for $800 million to $900 million, up from earlier guidance of $650 million to $850 million. The new forecast beat the FactSet consensus estimate of $641.3 million. Rivian Automotive – Shares of the electric vehicle manufacturer jumped about 6% after an upgrade by TD Cowen . The bank moved its rating on Rivian to buy from hold ahead of the launch of the company’s new R2 SUV vehicle, which is cheaper and smaller than its R1S model, and on the belief that electric vehicle demand will revive in the U.S. Vertex Pharmaceuticals — Vertex Pharmaceuticals shares advanced 8% after the biotech company said a drug met its goals in a late-stage trial for IgA nephropathy, a chronic condition that can lead to kidney failure. — CNBC’s Darla Mercado, Sarah Min, Davis Giangiulio, Michelle Fox, Yun Li and Pia Singh contributed reporting Markets shift and headlines fade, but the core principles of building long-term wealth remain constant. Join us for our third CNBC Pro LIVE, where investors of all backgrounds – from financial professionals to everyday individuals – come together to cut through the noise and gain actionable strategies for smarter, more disciplined investing. No matter where you’re starting from, you’ll leave with clearer thinking, stronger strategies. Enter your email here to get a discount code.
